Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider (NYSE:PFE)
1. Pfizer's current price is $26.55, seen as undervalued. 2. DCF analysis suggests a fair value of ~$50 per share. 3. Key focus areas include improving R&D and capital allocation. 4. Patent expiries and price regulations pose significant headwinds. 5. Success of danuglipron could alter Pfizer's competitive landscape.